These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma]. Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387 [TBL] [Abstract][Full Text] [Related]
5. Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining Hatakeyama J; Ono T; Takahashi M; Oda M; Shimizu H Neurol Med Chir (Tokyo); 2021 Jun; 61(6):367-375. PubMed ID: 33967177 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis. Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme. Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558 [TBL] [Abstract][Full Text] [Related]
8. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients. Shi X; Zhang X; Yi C; Wang X; Chen Z; Zhang B Clin Nucl Med; 2013 Feb; 38(2):98-102. PubMed ID: 23334122 [TBL] [Abstract][Full Text] [Related]
9. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136 [TBL] [Abstract][Full Text] [Related]
10. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745 [TBL] [Abstract][Full Text] [Related]
11. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma. Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915 [TBL] [Abstract][Full Text] [Related]
12. Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma. Kawase Y; Yamamoto Y; Kameyama R; Kawai N; Kudomi N; Nishiyama Y Mol Imaging Biol; 2011 Dec; 13(6):1284-9. PubMed ID: 21042866 [TBL] [Abstract][Full Text] [Related]
13. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer. Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography. Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328 [TBL] [Abstract][Full Text] [Related]
15. Quantitative and Visual Characteristics of Primary Central Nervous System Lymphoma on Liu D; Kong Z; Wang Y; Chen W; Wang Y; Chen W; Liu L; Dang Y; Ma W; Wang Y; Cheng X Interdiscip Sci; 2019 Jun; 11(2):300-306. PubMed ID: 31264053 [TBL] [Abstract][Full Text] [Related]
16. Assessment of biological parameters in head and neck cancer based on in vivo distribution of Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858 [TBL] [Abstract][Full Text] [Related]
17. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. Kawai N; Okubo S; Miyake K; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T Ann Nucl Med; 2010 Jun; 24(5):335-43. PubMed ID: 20379859 [TBL] [Abstract][Full Text] [Related]
18. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma? Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204 [TBL] [Abstract][Full Text] [Related]
19. Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma. Gupta M; Gupta T; Purandare N; Rangarajan V; Puranik A; Moiyadi A; Shetty P; Epari S; Sahay A; Mahajan A; Janu A; Bagal B; Menon H; Kannan S; Krishnatry R; Sastri GJ; Jalali R CNS Oncol; 2019 Dec; 8(4):CNS46. PubMed ID: 31779471 [No Abstract] [Full Text] [Related]
20. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma. Kawai N; Miyake K; Yamamoto Y; Nishiyama Y; Tamiya T Biomed Res Int; 2013; 2013():247152. PubMed ID: 23844359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]